Even if it will take a while before the subscription period at Synlap starts, the question for investors is already how they can be part of the healthcare growth trend. It is expected, for example, that the new mRNA technology may also be used for other drugs and that there will be breakthroughs in many diseases in the coming years. Regardless of the research success of the pharmaceutical companies and regardless of whether active ingredients actually prevail: One industry should definitely benefit: the medical service providers.